O Gonzalez-Ramella1,2, P C Ortiz-Lazareno3, X Jiménez-López1,2, S Gallegos-Castorena1,2, G Hernández-Flores3, F Medina-Barajas1,2, J Meza-Arroyo3, L F Jave-Suárez3, J M Lerma-Díaz3,4, F Sánchez-Zubieta1,2, A Bravo-Cuellar5,6. 1. Instituto de Investigación en Cáncer Infantil y de la Adolescencia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. 2. Department of Pediatric Hematology and Oncology, Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico. 3. División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Sierra Mojada 800, Col. Independencia, 44340, Guadalajara, Jalisco, Mexico. 4. Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos, Jalisco, Mexico. 5. División de Inmunología, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Sierra Mojada 800, Col. Independencia, 44340, Guadalajara, Jalisco, Mexico. abravocster@gmail.com. 6. Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos, Jalisco, Mexico. abravocster@gmail.com.
Abstract
PURPOSE:Pentoxifylline (PTX) has been shown to increase chemotherapy-induced apoptosis. A clinical trial was developed to evaluate the effect of the addition of PTX to the induction steroid window phase in children with acute lymphoblastic leukemia (ALL). METHODS:Thirty-two children were enrolled on this study. Children with a new diagnosis of ALL were randomly assigned to receive prednisone (PRD) 40 mg/m(2)/day only during the 7-day treatment pre-phase (PRD group, 11 patients) or to receive PRD with PTX (10 mg/kg/day) (PTX group, 11 patients); the control group included children with normal bone marrow (10 patients). Bone marrow aspiration (BMA) was performed at diagnosis (day -7) in all groups, and at day 0 (end of PRD window) for patients with ALL (PRD and PTX groups). Apoptosis was evaluated by flow cytometry (FC) using Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) stains. Statistical analysis was performed using the Mann-Whitney U test. RESULTS:Apoptotic index at day -7 was similar in all groups. However, at day 0 post-treatment, apoptosis was significantly higher in the PTX group than in the PRD group (p < 0.001). There were no serious adverse effects associated with PTX. CONCLUSIONS:PTX potentiates blast apoptosis induced by PRD in children with ALL during steroid window phase.
RCT Entities:
PURPOSE:Pentoxifylline (PTX) has been shown to increase chemotherapy-induced apoptosis. A clinical trial was developed to evaluate the effect of the addition of PTX to the induction steroid window phase in children with acute lymphoblastic leukemia (ALL). METHODS: Thirty-two children were enrolled on this study. Children with a new diagnosis of ALL were randomly assigned to receive prednisone (PRD) 40 mg/m(2)/day only during the 7-day treatment pre-phase (PRD group, 11 patients) or to receive PRD with PTX (10 mg/kg/day) (PTX group, 11 patients); the control group included children with normal bone marrow (10 patients). Bone marrow aspiration (BMA) was performed at diagnosis (day -7) in all groups, and at day 0 (end of PRD window) for patients with ALL (PRD and PTX groups). Apoptosis was evaluated by flow cytometry (FC) using Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) stains. Statistical analysis was performed using the Mann-Whitney U test. RESULTS: Apoptotic index at day -7 was similar in all groups. However, at day 0 post-treatment, apoptosis was significantly higher in the PTX group than in the PRD group (p < 0.001). There were no serious adverse effects associated with PTX. CONCLUSIONS:PTX potentiates blast apoptosis induced by PRD in children with ALL during steroid window phase.
Authors: José Manuel Lerma-Díaz; Georgina Hernández-Flores; Jorge R Domínguez-Rodríguez; Pablo C Ortíz-Lazareno; Piedad Gómez-Contreras; Ramón Cervantes-Munguía; Daniel Scott-Algara; Adriana Aguilar-Lemarroy; Luis F Jave-Suárez; Alejandro Bravo-Cuellar Journal: Immunol Lett Date: 2005-11-18 Impact factor: 3.685
Authors: Juan F Navarro-González; Carmen Mora-Fernández; Mercedes Muros de Fuentes; Jesús Chahin; María L Méndez; Eduardo Gallego; Manuel Macía; Nieves del Castillo; Antonio Rivero; María A Getino; Patricia García; Ana Jarque; Javier García Journal: J Am Soc Nephrol Date: 2014-06-26 Impact factor: 10.121
Authors: C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling Journal: Leukemia Date: 2009-12-10 Impact factor: 11.528